系统性红斑狼疮感染临床特征与危险因素的系统综述与Meta分析
该系统综述与Meta分析纳入39项观察性研究(3709例感染SLE患者和10526例非感染SLE患者),发现血小板减少、贫血、低蛋白血症、低补体血症、CRP升高、SDI评分高、肾脏受累及糖尿病与SLE患者感染相关;糖皮质激素(尤其高剂量)和免疫抑制剂增加感染风险,而抗疟药(羟氯喹)为保护因素。
要点
- 感染SLE患者更常见血小板减少、贫血、低蛋白血症、低补体血症及肾脏受累。
- 高剂量糖皮质激素和免疫抑制剂(如环磷酰胺)增加感染风险,抗疟药为保护因素。
- 糖尿病、CRP升高及SDI评分高与感染风险增高相关。
核心结论
- 多种临床特征和实验室指标与SLE患者感染风险增高相关,糖皮质激素和免疫抑制剂增加风险,抗疟药为保护因素。
研究设计与样本
- 系统检索PubMed、Embase和Cochrane数据库(截至2019年9月),纳入39项观察性研究,共3709例感染SLE患者和10526例非感染SLE患者,采用随机/固定效应模型进行Meta分析。
主要发现
- 感染SLE患者中淋巴细胞减少(OR=2.738,95%CI 1.017-7.376,P=0.046,I2=81.4%)、血小板减少(OR=1.61,95%CI 1.4-1.85,P<0.001,I2=0%)、贫血(OR=2.294,95%CI 1.402-3.755,P=0.001,I2=83.0%)、低蛋白血症(OR=2.336,95%CI 1.408-3.876,P=0.001,I2=84.2%)、C3消耗(OR=1.890,95%CI 1.190-3.002,P=0.007,I2=77.4%)、糖尿病(OR=3.890,95%CI 2.450-6.160,P<0.001,I2=0%)、肌酐升高(OR=1.954,95%CI 1.646-2.320,P<0.001,I2=0.0%)、肾脏受累(OR=2.692,95%CI 2.000-3.623,P<0.001,I2=76.0%)、浆膜炎(OR=3.877,95%CI 0.995-15.110,P=0.051,I2=79.1%)及使用类固醇免疫抑制剂(OR=3.116,95%CI 1.959-4.957,P<0.001,I2=77.9%)的发生率显著更高。
- 感染SLE患者的泼尼松平均剂量更高(SMD=2.088,95%CI 1.196-2.981,P<0.001,I2=97.8%),抗疟药使用率更低(OR=0.634,95%CI 0.451-0.892,P=0.009,I2=56.0%)。
- 感染SLE患者的24小时尿蛋白(SMD=0.560,95%CI 0.300-0.810,P<0.001,I2=0%)、CRP(SMD=0.437,95%CI 0.184-0.691,P=0.001,I2=68.6%)及SDI(SMD=0.451,95%CI 0.238-0.664,P<0.001,I2=0.0%)水平更高,白蛋白水平更低(SMD=-0.400,95%CI -0.610--0.200,P<0.001,I2=0.0%)。
- 经FDR校正后,淋巴细胞减少和浆膜炎不再与感染发生相关,其余因素仍与SLE感染相关。
关键数值与推荐
- 淋巴细胞减少OR=2.738(95%CI 1.017-7.376,P=0.046,I2=81.4%),血小板减少OR=1.61(95%CI 1.4-1.85,P<0.001,I2=0%),贫血OR=2.294(95%CI 1.402-3.755,P=0.001,I2=83.0%)。
- 低蛋白血症OR=2.336(95%CI 1.408-3.876,P=0.001,I2=84.2%),C3消耗OR=1.890(95%CI 1.190-3.002,P=0.007,I2=77.4%),糖尿病OR=3.890(95%CI 2.450-6.160,P<0.001,I2=0%)。
- 肌酐升高OR=1.954(95%CI 1.646-2.320,P<0.001,I2=0.0%),肾脏受累OR=2.692(95%CI 2.000-3.623,P<0.001,I2=76.0%),浆膜炎OR=3.877(95%CI 0.995-15.110,P=0.051,I2=79.1%)。
- 使用类固醇免疫抑制剂OR=3.116(95%CI 1.959-4.957,P<0.001,I2=77.9%),泼尼松平均剂量SMD=2.088(95%CI 1.196-2.981,P<0.001,I2=97.8%),抗疟药使用OR=0.634(95%CI 0.451-0.892,P=0.009,I2=56.0%)。
- 24小时尿蛋白SMD=0.560(95%CI 0.300-0.810,P<0.001,I2=0%),CRP SMD=0.437(95%CI 0.184-0.691,P=0.001,I2=68.6%),SDI SMD=0.451(95%CI 0.238-0.664,P<0.001,I2=0.0%),白蛋白SMD=-0.400(95%CI -0.610--0.200,P<0.001,I2=0.0%)。
临床怎么用
- 对具有血小板减少、贫血、低蛋白血症、低补体血症、CRP升高、SDI评分高、肾脏受累及糖尿病的SLE患者应警惕感染风险。
- 使用高剂量糖皮质激素或免疫抑制剂(如环磷酰胺)的SLE患者需加强感染监测,抗疟药(羟氯喹)可能降低感染风险。
局限性
- 纳入研究均为观察性研究,可能存在混杂偏倚;部分指标异质性较高(如淋巴细胞减少I2=81.4%);肾脏受累存在发表偏倚但未影响合并估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Infection is one of the major causes of morbidity and mortality in systemic lupus erythematosus (SLE) patients. We conducted a systematic review and meta-analysis to investigate the clinical characteristics and risk factors of infection in SLE by comparing demographic factors, laboratory data, clinical features, and therapeutic factors between infection and non-infection SLE patients. METHODS: PubMed, Embase, and Cochrane databases were searched systematically without restricting the language or year (up to September 2019) by using MeSH terms and keywords pertaining to SLE and infection. Three independent reviewers selected all observational studies based on the established inclusion criteria. Odds ratio (OR) and standardized mean difference (SMD) along with 95% confidence intervals (CI) were used and the analyses were carried out by using a random/fixed-effects model. When necessary, different subgroup and sensitivity analyses were conducted. Study quality was assessed by the modified version (nine-star scoring system) of the Newcastle-Ottawa Scale (NOS) and publication bias was evaluated by funnel plots, and Egger's and Begg's tests. RESULTS: In total, we included 39 studies (3709 infection SLE patients and 10526 non-infection SLE patients) based on the inclusion criteria. Compared with the SLE patients without infection, we found that infected SLE patients had a significantly higher incidence rate of the following: 1) lymphopenia (OR = 2.738 95%CI (1.017-7.376), P = 0.046, I2 = 81.4%), 2) thrombocytopenia (OR = 1.61 95%CI (1.4-1.85), P<0.001, I2 = 0%), 3) anemia (OR = 2.294 95%CI (1.402-3.755), P = 0.001, I2 = 83.0%), 4) hypoproteinemia (OR = 2.336 95%CI (1.408-3.876), P = 0.001, I2 = 84.2%), 5) C3 consumed (OR = 1.890 95%CI (1.190-3.002), P = 0.007, I2 = 77.4%), 6) diabetes mellitus (OR = 3.890 95%CI (2.450-6.160), P < 0.001, I2 = 0%), 7) elevated creatinine (OR = 1.954 95%CI (1.646-2.320), P < 0.001, I2 = 0.0%), 8) renal involvement (OR = 2.692 95%CI (2.000-3.623), P < 0.001, I2 = 76.0%), 9) serositis (OR = 3.877 95%CI (0.995-15.110), P = 0.051, I2 = 79.1%), and 10) use of steroid immunosuppressants (OR = 3.116 95%CI (1.959-4.957), P < 0.001, I2 = 77.9%). Furthermore, infected SLE patients had a significantly higher mean dose of prednisone (SMD = 2.088 95%CI (1.196-2.981), P < 0.001, I2 = 97.8%). In addition, SLE patients with infection showed a significantly lower incidence of antimalarial drug use (OR = 0.634 95%CI (0.451-0.892), P = 0.009, I2 = 56.0%). Infected SLE patients had a significantly higher level of 1) 24-h urinary protein (SMD = 0.560 95%CI (0.300-0.810), P < 0.001, I2 = 0%), 2) CRP (SMD = 0.437 95%CI (0.184-0.691), P = 0.001, I2 = 68.6%), and 3) SLE Collaborating Clinics damage index (SDI) (SMD = 0.451 95%CI (0.238-0.664), P < 0.001, I2 = 0.0%), along with a significantly lower level of albumin (SMD = -0.400 95%CI (-0.610--0.200), P < 0.001, I2 = 0.0%). After adjustment for false discovery rate (FDR), lymphopenia and serositis were no longer associated with the occurrence of infection; however, the remaining factors were still associated with infection in SLE. According to the nine-star scoring system of NOS, 71.79% of the studies were considered as high methodological quality (low risk of bias). No significant publication bias, except for renal involvement, was detected from funnel plots or Egger's and Begg's test, while this publication bias of renal involvement did not impact the pooled estimates. CONCLUSION: We identified many factors including thrombocytopenia, anemia, hypoproteinemia, hypocomplementemia, hypoalbuminemia, higher level of CRP, higher SDI score, renal involvement and diabetes mellitus that were associated with infection in SLE patients. In addition, glucocorticoids (especially high-dose) and immunosuppressants (e.g. cyclophosphamide) rendered SLE patients more susceptible to infection, while antimalarial drug administration (hydroxychloroquine) was a protective factor against infection in SLE patients. SLE patients with the above clinical characteristics and risk factors might be at high risk from infection, which might contribute to the early identification of infection in SLE patients for better prognosis.
引用
- Yuan Q, Xing X, Lu Z, et al. Clinical characteristics and risk factors of infection in patients with systemic lupus erythematosus: A systematic review and meta-analysis of observational studies. Semin Arthritis Rheum. 2020. PMID: 32911280. doi:10.1016/j.semarthrit.2020.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。